Roche’s RHHBY member company, Genentech, announced the FDA approval of TNKase (tenecteplase), a thrombolytic or ...

Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the standard 60-minute infusion of alteplase.

High-risk acute pulmonary embolism affects around 5% of all pulmonary embolisms and can take a dramatic course even in young ...

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

Researchers at Karolinska Institutet have identified a new mechanism that may improve the treatment of ischemic stroke. The ...

The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according ...

Ischemic stroke continues to rank among the top causes of death and long-term disability globally. While advances in acute treatments like clot retrieval and thrombolysis have improved outcomes, the ...

The FDA has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in ...

Researchers at Karolinska Institutet have identified a new mechanism that may improve the treatment of ischemic stroke. The ...

For patients with acute ischemic stroke (AIS) whose symptoms began 4.5 to 24 hours earlier, alteplase is associated with a higher percentage of patients achieving a score of 0 or 1 on the modified ...

For patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, de-escalating dual antiplatelet therapy (DAPT) to P2Y12 inhibitor monotherapy is associated with lower ...

According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...